COMPANY PROFILE

invIOs

Explore full profile

Innovative biotechnology company developing personalized cancer treatments with next-generation technologies

Vienna, AustriaFounded 2022Biotech & Life Sciences

Valuation $50–100M Last recorded · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About invIOs

invIOs is a pioneering biotechnology company focused on developing individualized treatments for cancer patients. Operating in the healthcare and biotechnology sectors, invIOs leverages cutting-edge technologies to create personalized therapies aimed at improving patient outcomes. The company primarily serves patients diagnosed with various forms of cancer, offering them advanced treatment options that are tailored to their specific medical needs.

invIOs operates on a business-to-consumer (B2C) model, directly engaging with patients and healthcare providers to deliver its innovative solutions. Revenue is generated through the development, approval, and commercialization of its proprietary therapies. By focusing on personalized medicine, invIOs aims to transform the standard of care in oncology, making treatments more effective and reducing side effects.

The company is committed to sustainability and innovation, continuously investing in research and development to stay at the forefront of biotechnology. invIOs also emphasizes a healthy work-life balance for its employees, fostering a motivated and dedicated workforce.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2022
Headquarters: Vienna, Austria
Employees: 14
Open positions: None listed
Dealroom signal: 55.8/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Oct 2024	$9M	$36M	Ligand Pharmaceuticals	↗
EARLY VC✓Equity / VC	Jul 2024	$4M	$16M	Ligand Pharmaceuticals	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

invIOs website traffic

Latest recorded traffic for invIOs is 2.6K monthly website visits, up 85.7% over the last three months. invIOs's team grew 0% over the past year.

Latest monthly visits2.6K 3-month web change+85.7% 1-year team growth0%

Monthly website visitsDec 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CPCPTxAt CPTx, new treatment paradigms are developed to address unmet medical challenges, with an initial focus on infectious diseases	Planegg, Germany	Operational	49	$29M	$116M
RARamanomicsRapid diagnostic platform for antimicrobial resistance detection	Oxford, United Kingdom	Operational
STSolve TherapeuticsTargeted cancer therapies enhancing safety and precision	San Diego, United States	Operational
AVAviadoBioPrecision gene therapies for neurodegenerative disorders	London, United Kingdom	Operational
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
PEPerformsApplies patented nanotechnology to enhance solubility and delivery of an endogenous anti‑inflammatory molecule for psoriasis treatment	Modena, Italy	Operational
EBExeVir BioCamelid-derived antibody therapies for infectious diseases	Ghent, Belgium	Operational
NTNature’s ToolboxNature's Toolbox (NTx) is advancing the healthcare industry with their cutting-edge biomanufacturing solutions	Santa Fe, United States	Operational